Émeline Colomba

3.6k total citations
71 papers, 526 citations indexed

About

Émeline Colomba is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Émeline Colomba has authored 71 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 40 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Émeline Colomba's work include Renal cell carcinoma treatment (23 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Endometrial and Cervical Cancer Treatments (12 papers). Émeline Colomba is often cited by papers focused on Renal cell carcinoma treatment (23 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Endometrial and Cervical Cancer Treatments (12 papers). Émeline Colomba collaborates with scholars based in France, Italy and Spain. Émeline Colomba's co-authors include Laurence Albigès, Bernard Escudier, Lisa Derosa, Annalisa Guida, Yohann Loriot, Karim Fizazi, Ronan Flippot, David Capper, Andreas von Deimling and Cristi Marin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Émeline Colomba

62 papers receiving 518 citations

Peers

Émeline Colomba
Roman Groisberg United States
Federica Zoratto Italy
Elena Poddubskaya Russia
Fangfang Lü China
Dénes Csonka Switzerland
Ran Xie United States
Herb Kotz United States
Karel Cwiertka Czechia
C. Cebotaru Romania
Kuniko Sunami Japan
Roman Groisberg United States
Émeline Colomba
Citations per year, relative to Émeline Colomba Émeline Colomba (= 1×) peers Roman Groisberg

Countries citing papers authored by Émeline Colomba

Since Specialization
Citations

This map shows the geographic impact of Émeline Colomba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Émeline Colomba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Émeline Colomba more than expected).

Fields of papers citing papers by Émeline Colomba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Émeline Colomba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Émeline Colomba. The network helps show where Émeline Colomba may publish in the future.

Co-authorship network of co-authors of Émeline Colomba

This figure shows the co-authorship network connecting the top 25 collaborators of Émeline Colomba. A scholar is included among the top collaborators of Émeline Colomba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Émeline Colomba. Émeline Colomba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kanayama, Mayuko, Émeline Colomba, Sarah M. Nielsen, et al.. (2025). Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant. Prostate Cancer and Prostatic Diseases.
2.
3.
Négrier, Sylvie, Loı̈c Mourey, Ellen Blanc, et al.. (2025). Cabozantinib in patients (pts) with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC): Results of the multicenter CABRAMET phase II trial (NCT03967522).. Journal of Clinical Oncology. 43(5_suppl). 533–533. 1 indexed citations
4.
5.
Agarwal, Neeraj, Daniel Castellano, Teresa Alonso‐Gordoa, et al.. (2024). A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1. Clinical Cancer Research. 30(11). 2377–2383. 6 indexed citations
6.
Colomba, Émeline, Domenica Lorusso, Helen Mackay, et al.. (2023). 748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775. Annals of Oncology. 34. S512–S513. 2 indexed citations
7.
Auclin, Édouard, Anna Patrikidou, Laura Mezquita, et al.. (2023). Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma. Cancers. 15(4). 1066–1066. 10 indexed citations
8.
Bayle, Arnaud, Damien Vasseur, Claudio Nicotra, et al.. (2023). Clinical utility of plasma ctDNA sequencing in metastatic urothelial carcinoma.. Journal of Clinical Oncology. 41(16_suppl). 4576–4576. 1 indexed citations
9.
Coquan, Elodie, Justine Lequesne, Émeline Colomba, et al.. (2022). 2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study). International Journal of Gynecological Cancer. 32. A14–A14.
10.
Colomba, Émeline, Luca Campedel, Clément Dumont, et al.. (2022). Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study. Cancers. 14(7). 1678–1678. 7 indexed citations
11.
Colomba, Émeline, Carolina Alves Costa Silva, Gwénaël Le Teuff, et al.. (2022). Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. Journal of Cachexia Sarcopenia and Muscle. 13(5). 2405–2416. 8 indexed citations
12.
Aldea, Mihaela, Rakiba Belkhir, Émeline Colomba, et al.. (2022). Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report. Frontiers in Immunology. 13. 920130–920130.
13.
Rassy, Elie, Cécile Dalban, Émeline Colomba, et al.. (2022). Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. Clinical Genitourinary Cancer. 20(5). 488–494. 13 indexed citations
14.
Honoré, Charles, Olivier Mir, Arthur Géraud, et al.. (2021). Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer: An Alternative to Systematic Transfer. JCO Oncology Practice. 17(9). e1311–e1317. 3 indexed citations
15.
Carril-Ajuria, Lucía, Émeline Colomba, Luigi Cerbone, et al.. (2021). Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma. European Journal of Cancer. 151. 106–114. 24 indexed citations
16.
Honoré, Charles, Arthur Géraud, Nicolas Epaillard, et al.. (2021). RCP Pacifique : bilan après un an et 323 cancers rares et/ou complexes discutés. Bulletin du Cancer. 108(12). 1077–1084.
17.
Derosa, Lisa, Cécile Dalban, Émeline Colomba, et al.. (2021). 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N). Annals of Oncology. 32. S710–S710. 5 indexed citations
18.
Colomba, Émeline, Grégoire Marret, Giulia Baciarello, et al.. (2020). Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. European Journal of Cancer. 129. 117–122. 11 indexed citations
19.
Michels, Judith, Catherine Genestie, Ariane Dunant, et al.. (2020). Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry. Gynecologic Oncology. 160(1). 77–82. 1 indexed citations
20.
Massari, Francesco, Vincenzo Di Nunno, Annalisa Guida, et al.. (2020). Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. Clinical Genitourinary Cancer. 19(1). 32–40. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roman Groisberg Breakdown of academic impact, for papers by Federica Zoratto Breakdown of academic impact, for papers by Elena Poddubskaya Breakdown of academic impact, for papers by Fangfang Lü Breakdown of academic impact, for papers by Dénes Csonka Breakdown of academic impact, for papers by Ran Xie Breakdown of academic impact, for papers by Herb Kotz Breakdown of academic impact, for papers by Karel Cwiertka Breakdown of academic impact, for papers by C. Cebotaru Breakdown of academic impact, for papers by Kuniko Sunami
Rankless by CCL
2026